CNSI-Fe(II) / Sichuan Enray Pharma - LARVOL DELTA

Utility of cerebrospinal fluid multiplex polymerase chain reaction assay in children suspected of meningitis or encephalitis in a tertiary care hospital in Thailand. (PubMed, IJID Reg) - "The ME panel is a reliable tool for supporting the management of CNSinfections due to its high specificity and rapid turnaround time. However, the diversity ofpathogens that cause CNS diseases poses a challenge to its use in tropical countries."

Journal • Polymerase Chain Reaction • Chikungunya • CNS Disorders • Dengue Fever • Infectious Disease • Influenza • Pulmonary Disease • Respiratory Diseases • Tuberculosis

First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles‑Fe(II) complex trials. (PubMed, BMC Cancer) - P1 | "This case series provides preliminary clinical evidence that CNSI-Fe could weaken MDR and resensitize solid tumors to systemic therapy. These findings warrant biomarker-integrated expansion cohorts and Phase II trials of CNSI-Fe-based combinations with radiotherapy, chemotherapy, targeted therapy, and immunotherapy."

First-in-human • IO biomarker • Journal • P1 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Thyroid Gland Carcinoma • Vulvar Cancer

Photothermal-immunotherapy of colon carcinoma by carbon nanoparticle-Fe(II) complex with immunoadjuvant. (PubMed, Colloids Surf B Biointerfaces) - "As the only ferroptosis-based nanomedicine under clinical trial evaluation, carbon nanoparticle-Fe (II) complex (CNSI-Fe) not only induces ferroptosis in tumor cells, but also serves as photothermal conversion agents for tumor photothermal therapy...The combination treatments showed acceptable toxicity during in vivo evaluations. Our study offered a translatable strategy for next-generation ISV and would hopefully benefit the patients in near future."

Journal • CNS Tumor • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial (clinicaltrials.gov) - P2 | N=52 | Not yet recruiting | Sponsor: Sichuan Enray Pharmaceutical Sciences Company

New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: Sichuan Enray Pharmaceutical Sciences Company | Trial completion date: Feb 2024 ➔ Feb 2025 | Recruiting ➔ Completed | Trial primary completion date: Dec 2023 ➔ Sep 2024

Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Cervical Cancer • Cholangiocarcinoma • Colorectal Cancer • Endocrine Cancer • Gastric Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • Vulvar Cancer